欢迎访问西安瑞禧生物技术有限公司官方网站

图片名

全国订购热线:
18966759382

首页 > 新闻资讯 > 技术资讯

技术资讯
行业新闻 市场活动 技术资讯

Varenicline-d4,伐尼克兰-d4; CP 526555-d4「同位素标记抑制剂」

作者:瑞禧生物 发布时间:2025-06-11 10:02:18 次浏览

生物活性:Varenicline-d4 is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Varenicline-d4 相关抗体:
J-chain Antibody (YA1290)
PSCA Antibody (YA1479)
Butyrylcholinesterase Antibody (YA2460)
Nicotinic Acetylcholine Receptor alpha 4 Antibody (YA2616)
Nicotinic Acetylcholine Receptor alpha 5 Antibody (YA2659)
分子量:215.29
Formula:C13H9D4N3
CAS 号:2183239-01-0
非标记 CAS:249296-44-4
中文名称:伐尼克兰-d4
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (535 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Mihalak KB, et al. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.
 [Content Brief]
[3]. Bagdas D, et al. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.Neuropharmacology. 2018 Aug;138:72-79.
 [Content Brief]